Halozyme Reports First Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Halozyme Therapeutics (HALO) Tops Q1 EPS by 5c, Revenues Beat; Offers FY21 EPS Mid-Point Guidance Above Consensus, FY21 Revs. Mid-Point Views Below Consensus
May 10, 2021 4:57 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.37, $0.05 better than the analyst estimate of $0.32. Revenue for the quarter came in at $89 million versus the consensus estimate of $84.88 million.
"The first quarter marked a strong start to 2021 highlighted by record quarterly royalty revenue driven by the continued successful launch of subcutaneous DARZALEX® worldwide," said Dr. Helen Torley, president and chief executive officer. "Our pipeline of partnered product candidates using ENHANZE®... More
